OLD National Bancorp IN decreased its position in GlaxoSmithKline PLC (NYSE:GSK) by 11.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,594 shares of the pharmaceutical company’s stock after selling 1,960 shares during the period. OLD National Bancorp IN’s holdings in GlaxoSmithKline PLC were worth $672,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of the company. Koshinski Asset Management Inc. increased its position in shares of GlaxoSmithKline PLC by 5.6% in the first quarter. Koshinski Asset Management Inc. now owns 10,011 shares of the pharmaceutical company’s stock worth $422,000 after buying an additional 527 shares during the last quarter. Dynamic Advisors Solutions LLC increased its position in GlaxoSmithKline PLC by 1,411.4% in the first quarter. Dynamic Advisors Solutions LLC now owns 95,292 shares of the pharmaceutical company’s stock valued at $4,017,000 after buying an additional 88,987 shares in the last quarter. Augustine Asset Management Inc. increased its position in GlaxoSmithKline PLC by 23.6% in the first quarter. Augustine Asset Management Inc. now owns 17,585 shares of the pharmaceutical company’s stock valued at $741,000 after buying an additional 3,355 shares in the last quarter. GW&K Investment Management LLC increased its position in GlaxoSmithKline PLC by 17.8% in the first quarter. GW&K Investment Management LLC now owns 1,017,202 shares of the pharmaceutical company’s stock valued at $42,885,000 after buying an additional 153,555 shares in the last quarter. Finally, Raymond James Trust N.A. increased its position in GlaxoSmithKline PLC by 3.4% in the first quarter. Raymond James Trust N.A. now owns 132,266 shares of the pharmaceutical company’s stock valued at $5,576,000 after buying an additional 4,401 shares in the last quarter. Hedge funds and other institutional investors own 8.99% of the company’s stock.
GlaxoSmithKline PLC (NYSE GSK) traded down 0.48% on Thursday, reaching $39.05. 2,809,282 shares of the company traded hands. The company has a 50-day moving average price of $41.41 and a 200-day moving average price of $41.86. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $44.58. The company has a market capitalization of $95.44 billion, a P/E ratio of 37.77 and a beta of 1.03.
GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The firm had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. Equities research analysts expect that GlaxoSmithKline PLC will post $2.85 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be given a $0.491 dividend. This represents a $1.96 annualized dividend and a yield of 5.03%. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date is Wednesday, August 9th. GlaxoSmithKline PLC’s payout ratio is currently 197.00%.
Several equities analysts have issued reports on GSK shares. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 13th. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a research note on Tuesday, July 18th. Berenberg Bank upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research note on Friday, May 26th. TheStreet upgraded shares of GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research note on Friday, May 19th. Finally, Citigroup Inc. restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 27th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company’s stock. GlaxoSmithKline PLC has a consensus rating of “Hold” and an average target price of $44.67.
About GlaxoSmithKline PLC
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.
